NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

CytoTools AG (XETRA: T5O)

 
T5O Technical Analysis
5
As on 9th Aug 2024 T5O STOCK Price closed @ 0.32 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.62 & Strong Sell for SHORT-TERM with Stoploss of 2.41 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

T5OSTOCK Price

Open 0.34 Change Price %
High 0.34 1 Day -0.06 -15.79
Low 0.32 1 Week -0.07 -17.95
Close 0.32 1 Month -0.14 -30.43
Volume 5899 1 Year -2.52 -88.73
52 Week High 2.92 | 52 Week Low 0.30
 
XETRA Germany Most Active Stocks
LHAR 2.05 -20.23%
BBVA 5.00 -2.72%
BBVA 5.00 -2.72%
BBVA 5.00 -2.72%
BVBA 0.02 -60.00%
SNH 0.16 6.67%
SNH 0.16 6.67%
SNH 0.16 6.67%
PHIA 31.36 1.92%
PHIA 31.36 1.92%
 
XETRA Germany Top Gainers Stocks
PDA 2.73 196.74%
PDA 2.73 196.74%
PDA 2.73 196.74%
PDA 2.73 196.74%
PDA 2.73 196.74%
PDA 2.73 196.74%
PAG 0.02 100.00%
PAG 0.02 100.00%
PAG 0.02 100.00%
PAG 0.02 100.00%
 
XETRA Germany Top Losers Stocks
F03 0.56 -99.14%
F03 0.56 -99.14%
F03 0.56 -99.14%
F03 0.56 -99.14%
IQL 0.02 -66.67%
IQL 0.02 -66.67%
EIN3 60.20 -63.95%
EIN3 60.20 -63.95%
EIN3 60.20 -63.95%
LEO 0.04 -63.64%
 
 
T5O
Daily Charts
T5O
Intraday Charts
Whats New @
Bazaartrend
T5O
Free Analysis
 
T5O Important Levels Intraday
RESISTANCE0.36
RESISTANCE0.35
RESISTANCE0.34
RESISTANCE0.33
SUPPORT0.31
SUPPORT0.30
SUPPORT0.29
SUPPORT0.28
 
T5O Forecast November 2024
4th UP Forecast1.24
3rd UP Forecast0.95
2nd UP Forecast0.76
1st UP Forecast0.58
1st DOWN Forecast0.06
2nd DOWN Forecast-0.12
3rd DOWN Forecast-0.31
4th DOWN Forecast-0.6
 
T5O Weekly Forecast
4th UP Forecast1.03
3rd UP Forecast0.80
2nd UP Forecast0.66
1st UP Forecast0.52
1st DOWN Forecast0.12
2nd DOWN Forecast-0.02
3rd DOWN Forecast-0.16
4th DOWN Forecast-0.39
 
T5O Forecast2024
4th UP Forecast5.37
3rd UP Forecast3.75
2nd UP Forecast2.75
1st UP Forecast1.75
1st DOWN Forecast-1.11
2nd DOWN Forecast-2.11
3rd DOWN Forecast-3.11
4th DOWN Forecast-4.73
 
 
T5O Other Details
Segment EQ
Market Capital 33512958.00
Sector Financial Services
Industry Asset Management
Offical website >
 
T5O Address
T5O
 
T5O Latest News
 
Your Comments and Response on CytoTools AG
 
T5O Business Profile
CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company's therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urinary tract infections; Derma MP for the treatment of venous leg ulcers in Europe; CardioClean that is in preclinical stage for the treatment of restenosis, diabetis, and carotis-stenosis; and Cancer T17-n for cancer treatment in Europe. CytoTools has collaboration agreement with Activoris Medizintechnik GmbH to develop inhalation therapy for viral infections, such as COVID-19 and influenza. CytoTools AG was founded in 2000 and is based in Darmstadt, Germany. Address: Klappacher Strasse 126, Darmstadt, Germany, 64285
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service